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Abstract:
Background: Pnuemonia is a leading cause of morbidity and mortality worldwide and
children diagnosed with asthma have been shown to be at greatly increased risk of recurrent
Community-Acquired Pneumonia (CAP). CAP in asthmatic children can incur nearly double the
healthcare costs and lead to poorer outcomes during the course of the pneumonia infection.
Objective: This study seeks to determine if sputum (SP) samples may be used in the
pediatric population to better understand the microbiome environment during severe pneumonia
in place or in conjunction with the more commonly used nasopharyngeal (NP) samples.
Additionally, this study seeks to identify features of the microbiome associated with pneumonia
severity in asthmatic children.
Methods: Sputum and nasopharyngeal/oropharyngeal (NP/OP) samples were collected
from asthmatic children diagnosed with asthma upon admission to a hospital. Bacterial cultures
for known CAP pathogens using sputum samples, and PCR detection for viral pneumonia
pathogens on the NP/OP samples were performed. To study the microbiome, 16s rRNA analysis
of sputum and nasopharyngeal samples was performed and analysis conducted using a variety of
single and community-based analyses. Outcomes of interest were LOS > 4 days and admission
to the ICU.
Results: High relative abundance of CAP pathogens, including Moraxella and
Haemophilus, were associated with poorer CAP outcomes in both age groups for both ICU
admission and longer LOS. Similarly, a positive sputum culture result for Staphylococcus
aureus was found to be significantly associated with more severe pneumonia. Bacteroidetes was
associated with shorter LOS and Rothia association with longer LOS in several of the analyses.
Both conclusions are consistent with previous characterizations of the bacteria in the onset of
pneumonia and asthma. Moraxella was consistently associated with longer LOS and increased
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risk of ICU admission, consistent with its characterization as a minor CAP pathogen, but was
protective against longer LOS in the younger age group.
Conclusions: First, our study demonstrates that sputum samples may be used in a
pediatric population. Our findings demonstrate that many of the microbiome features previously
identified as being predictive of, or associated with, CAP, also serve to predict severe pneumonia
outcomes in this pediatric population, including longer Length of Stay (LOS) and Intensive Care
Unit (ICU) admission. However, certain inconsistencies in the trends in our data highlight the
need to perform microbiome analyses using many different approaches to fully understand the
complex relationships between the diverse commensal and pathogenic bacteria that comprise the
microbiome.
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Introduction:
Pneumonia is among the three leading causes of admission for pediatric patients and remains a
major cause of morbidity and mortality worldwide in pediatric populations (Parikh, 2014; VilaCorcoles, 2012). Pneumonia is most commonly found in children under four years of age and
adults sixty-five or older (Myles, 2009). From within the community, this so-named
Community-Acquired Pneumonia (CAP) has been primarily linked to four bacterium when of
bacterial etiology: Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus
and Moraxella catarrhalis (Cevey-Macherel, 2009). Recently, the widespread use of the 13valent conjugate pneumococcal vaccine targeting S. pnuemoniae has reduced the prevalence of
pneumonia in the population. Yet there remains a significant burden of pneumonia, as well as
possible concerns regarding continued efficacy of the vaccine due to increasing burden of nonvaccine S. pneumoniae serotypes (Maldonado, 2014). Within the U.S. population, asthmatics
represent a community who are at increased risk for developing pneumonia (Obert, 2012; Talbot,
2005; Maldonado, 2014; Patria, 2013). Asthma exacerbations are associated with increased
health care costs and poorer outcomes among patients, and these exacerbations can often be
caused by infections with CAP pathogens (Ivanova, 2012).
This relationship between asthma and pneumonia has been supported by a broad range of
biological data demonstrating an increased susceptibility towards infection, however the
mechanism of this increased susceptibility is not yet clear. In the pediatric population, asthmatic
patients have been shown to have a deficient cellular and humoral immune response to
Mycoplasma pneumoniae infection compared with non-asthmatic controls (Atkinson, 2009).
Some studies have looked at a genetically-determined immune response present in asthmatics,
mediating the susceptibility to pneumonia while others have looked at structural changes in the
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respiratory tract (McKeever, 2013). However, asthma diagnoses have also been associated with
the presence of pneumonia pathogens such as Human Rhinovirus (HRV), Chlamydophila
pneumoniae and Mycoplasma pneumoniae (Lu, 2014; Specjalski, 2011), as well as increased
diversity within the bronchial microbiota, mainly attributed to the presence of pathogenic
bacteria (Hilty, 2010; Huang, 2013). Pathogenic proteobacteria, particularly Haemophilus spp.,
were far more common in asthmatic patients, both adults and children, while Bacteroidetes,
especially Prevotella spp., were less frequent in the asthmatic population and possibly played a
protective role against invasion (Hilty, 2010). Disturbed microbiota have often been implicated
as a risk factor for susceptibility toward invading pathogens and the development of pneumonia.
In this study we seek to investigate the relationship between the microbiome and asthma by
looking at the severity of disease within pneumonia patients. Most studies pneumonia have
focused on the relationship between the microbiome and the risk of developing pneumonia
(Boutin, 2013). To the best of our knowledge, no study has yet looked at the relationship
between the microbiome and the severity of pneumonia within the asthmatic population.
Previous culture based analyses have also revealed specific etiologies associated with pneumonia
and the onset of pneumonia. Within pediatric patients, S. pneumoniae (46) and rhinovirus (29)
were found to be the most common microbes detected in CAP (Lahti, 2009). A prospective
cohort study found that neonatal airway colonization by S. pneumoniae, H. influenzae or M.
catarrhalis led to increased risk of pneumonia and bronchiolitis in the first three years of life,
independent of asthma diagnosis (Vissing, 2013). When nasopharyngeal samples were used to
diagnose the etiology of CAP in pediatric patients diagnosed with acute asthma, 35% of the
pediatric patients were diagnosed with viral pneumonia (Isaacs, 1989). However, in the same
study radiographic tests and clinical criteria were unable to distinguish between viral and
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bacterial pneumonia, highlighting the need for other tests in the clinical diagnosis of the
pneumonia pathogen.
Additionally, there are questions surrounding the validity of various diagnostic tests used to
detect and diagnose pneumonia. Nasopharyngeal samples are often used in diagnosis, but may
be susceptible to underdiagnosis of S. aureus and overdetection of asymptomatic pathogenic
bacteria that are capable of colonizing the nasopharynx (Isaacs, 1989; Nolte, 2008; Kumar,
2008). Induced sputum samples have previously been used to test for the presence or absence of
CAP pathogens in pneumonia patients (Specjalski, 2011). Sputum samples have been proposed
as an alternative strategy to enhance detection of some pathogens. Sputum samples were
successfully used in a recent study of pediatric populations diagnosed with CAP and were used
to microbiologically identify the causative agent of the pneumonia in 90% of cases (Lahti, 2009).
Moreover, one-quarter of all of the identified bacterial pathogens were only detected in the
sputum, not in the nasopharyngeal samples (Lahti, 2009). In this study we seek to assess the
relative value of the sputum and the nasopharyngeal samples in predicting pneumonia disease
severity and their value as surrogates for evaluating the lung microbiome.
Methods:
These data and samples were all from the recently conducted Centers for Disease Control (CDC)
study on the Etiology of Pneumonia in the Community (EPIC) (Jain, 2015). The EPIC study was
a prospective, multi-site, population-based active surveillance study to determine the incidence
and etiology of CAP in children (Jain, 2015). Subjects under 18 years of age were identified and
eligible for entry into the study when seeking medical care for respiratory illness to Le Bonheur
Children’s Hospital (LBCH) or the LBCH catchment area in Memphis Tennessee. Patients were
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examined for clinical evidence of pneumonia, and the final study sample was limited to only
those patients with an abnormal chest X-ray confirming the presence of pneumonia. Upon
enrollment in the study, patients completed a full medical history questionnaire, and provided
samples of whole blood, induced sputum sample (SP), blood culture, nasopharyngeal swab (NP),
oropharyngeal swab (OP) and serum samples at admission (acute). The following tests were
performed on the specimens: culture of blood and NP/OP secretions for bacteria, real-time
polymerase chain reaction (PCR) for influenza viruses A and B, respiratory syncytial virus
(RSV), human metapneumovirus (hMPV), parainfluenza virus (PIV) 1, 2 and 3, coronaviruses
229E, OC43, NL63 and HKU1, adenovirus, rhinoviruses, S. pneumoniae, Legionella
pneumophila, M. pneumoniae, and Chlamydia pneumoniae (NP/OP secretions), PCR for S.
pneumoniae and Group A Streptococcus (whole blood) , Enzyme Immunoassay (EIA) (Remel)
for M. pneumoniae, Microimmunofluorescence (MIF) for C. pneumoniae (serum), EnzymeLinked Immunosorbent Assay (ELISA) for influenza viruses A and B, RSV, hMPV, and PIV 1,
2, 3, PCR for S. aureus using whole blood, and the culture of induced sputum for bacteria in
children. The final sample size was 208 pediatric patients when the sample was limited only to
children who had both their NP/OP and SP sample successfully amplify for the 16S ribosomal
analysis, as well as having X-ray confirmed pneumonia, and a confirmed history of asthma.
16s RNA Analysis:
The microbiome samples were analyzed through the hypervariable regions V4 of the 16S
ribosomal RNA using bar-coded 16sRNA primers as previously described (Caporaso, 2012).
Initial cleaning, binning, and processing of sequence reads were done using Btrim (Kong, 2011).
Sequences were scanned for linkers and primers while allowing for two errors, and primer
sequences were removed from each sequence read. Reads missing the 5’-end primer were
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removed from the data set. Bar codes were identified, allowing for one error, and trimmed after
sequence reads were binned into separate FASTA files.
Sequences were aligned using Infernal 1.1 available from the Ribosomal Database Project (RDP)
(Cole, 2009). Strict alignment criteria were set to minimize the number of chimeras: all
sequences had to align to at least 200 bp of the 16S rRNA gene, and any sequence aligning
outside of the 27 or the 338 position of the 16s rRNA gene was discarded. Taxonomic
identification of samples was achieved using the RDP Bayesian classifier tool at 90% confidence
from the RDP pipeline on the RDP database project. Those bacteria that failed to classify to an
order were labeled as “unclassified”. Following classification, sequence reads were then
clustered (RDP pipeline) into Operational Taxonomic Units (OTU’s), defined in an iterative
process beginning first with genus level identification, and then moving up to the next taxonomic
level when the lower level grouping was not available. Individual samples were assessed for
measures of microbiome diversity, calculating the evenness and Shannon Index (RDP pipeline).
Statistical Analysis:
The population was stratified into older than and younger than five years of age for all analyses
due to differences between the populations and potential complications with differences in
diagnostic practices for asthma in these age groups (asthma is not considered to be an
appropriate diagnosis prior to five years of age). Disease severity was measured through hospital
Length of Stay (LOS) as a dichotomous categorical variable, categorizing those with LOS >4
days as having the outcome of interest. This cutoff was chosen because the top quartile of LOS
(q4 >4.29 days) closely correlated with those having LOS greater than four days (26.6% of study
population had LOS >4 days). Intensive Care Unit (ICU) admission was also used in a subgroup
analysis as a dichotomous variable in patients older than five years of age; the analysis was only
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performed in the older age group as the frequency of ICU visitation was not high enough in the
lower age group to provide adequate power to the analysis. Unadjusted associations for outcome
variables LOS and ICU admission, as well as potential confounders, presence of cultured
pathogens, and diversity measures were calculated using a chi–square test or t-test as
appropriate.
For all subsequent analyses, a cutoff of 0.6% mean relative abundance within either the NP/OP
or the SP samples was used for each taxa. This left 26 taxa for subsequent analyses and all
remaining taxa or unclassified sequences were combined into the category “meta_other”. We
used several measures of microbial community structure. 1) Principal component analysis
(PCA) was performed in SAS 9.4 (SAS Institute, Cary NC) on both the SP and NP/OP 16S RNA
samples to determine associated groups of bacteria, and the resulting factor scores being used in
the logistic regression. 2) Linear Discriminant Analysis (LDA) was performed using LefSE to
determine significantly differentiated taxa between those with and without severe disease, as
well as between the NP/OP and SP samples within each category (Segata, 2011). Each
participant was then assigned as being either in the lower three or top quartile with respect to the
relative abundance of each of the significantly enriched taxa. These dichotomous categorical
variables for significantly enriched taxa were then input into a logistic regression model. 3)
Lastly, a community typing analysis using SimClust (Walesiak, 2014) in R (R Core Team, 2014)
was used to cluster patients into groups with similar microbiome profiles. RandomForest (Liaw,
2012) in R was then used to determine the significantly discriminant features of the community
types.
All logistic regressions were stratified by age and performed separately by outcome variable in
SAS 9.4, resulting in three models, unless stated otherwise: (i) LOS outcome in the < 5 age
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group, (ii) LOS outcome in the ≥ 5 age group and lastly (iii) ICU outcome in the ≥ 5 age group.
The first logistic regression models were created using the diversity measures for evenness and
the Shannon Index. Community types were used as a categorical variable in logistic regression
models. Additionally, heat maps of the community types were created in R by determining the
proportion of patients of each community type in the fourth quartile for relative abundance of
each taxa. Potential confounders included sex, race, education, type of facility the patient was
admitted from, presence of co-morbidities, prior antibiotic use, oral steroid use, inhaled steroid
use, and vaccination history for seasonal influenza, pneumococcal-7 or 13 conjugate and H.
influenza B. Pathogens included S. pneumoniae, S. aureus, M. catarrhalis, H. influenzae, M.
pneumoniae, Rhinovirus, RSV, adenovirus, coronavirus, H. parainfluenzae, and hMPV.
Results and Discussion:
1. Study Population
All of the analyses were performed upon an age-stratified population, where children were
grouped into the younger category less than five years of age, and the older age group of children
from five to less than eighteen years of age. This cutoff was selected due to the difficulties and
controversy in diagnosing asthma in those under five years of age (Mayo Clinic Staff, 2015).
Official guidelines dictate that asthma cannot be properly diagnosed in children under the age of
five as many of these children will eventually grow out of the asthma as they become older. This
has several implications for this study, namely that the population of children diagnosed with
asthma under the age of five may well be a different population than those who maintain their
asthma diagnosis past the age of five. Thus, we elected to stratify the analysis by age for all of
the analyses in this study.
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Demographic, vaccination and clinical characteristics of the stratified study population are
described in Table 1 by LOS and Table 2 by ICU admission. Within both age groups, there were
slightly more males than females, with 44.4% and 42.9% of the population being female in the
younger and older age groups respectively. Most of the population was admitted into the
hospital directly from home, 82.5% and 63.6% coming from home in the younger and older age
group respectively. Although 7.1% and 10.4% came from outpatient clinics in the younger and
older age groups respectively; and 9.5% of the younger and 26.0% of the older age group came
from another hospital. The majority of the study’s population was black, with 82.5% and 88.3%
of the population identifying as black in the younger and older age groups respectively, with the
rest of the population roughly evenly split between white and other races. Race does appear to
be a significant unadjusted association with LOS in the younger age group (p-value = 0.014).
There was no significant unadjusted association found between LOS and ICU admission with
education, presence of co-morbidities, prior antibiotic history, oral steroid use, inhaled steroid
use, and H. Influenzae vaccination. Nearly all of the study’s population had previously received
the Pneumococcal-7 or 13 conjugate vaccine, though coverage was not as high among the older
age group (81.8%), with the pneumococcal vaccine appearing to have a significant unadjusted
association with LOS in the older age group.
Tables 3 and 4 present the unadjusted associations between the different culture results for the
CAP bacterial pathogens, while Tables 5 and 6 presents the same for the PCR tests for the viral
pathogens and bacteria. There did not appear to be any association between a positive culture for
S. pneumoniae, M. catarrhalis, H. influenzae, and M. pneumoniae and either of the disease
outcomes in the analysis. However, a positive S. aureus culture did appear to have a significant
association with increased LOS in the younger age group (p<0.001). Similarly, there was no
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significant association found between a positive PCR viral test for rhinovirus, RSV, adenovirus,
coronavirus, PIV, or hMPV, and either of the pneumonia severity markers, LOS or ICU
admission.

2. Differences between the NP/OP and SP samples within the population.
Relationship between diversity measures and disease severity within NP/OP and SP samples:
There were significant differences found between the NP/OP and SP samples with respect to the
diversity indices. The SP samples were consistently less diverse with respect to both evenness
and the Shannon Index in the total study population (Evenness: p=0.031; Shannon: p <0.001) as
well the younger age group (Evenness: p < 0.001; Shannon: p <0.001) (Table 7). However,
within the older age group, the SP samples were actually found to be significantly more diverse
than the NP/OP samples with respect to the samples’ evenness (p=0.018), though there was no
significant difference found in the Shannon Index. Thus the SP sample does appear to be
capturing a different microbiota than the NP/OP samples. However, despite the differences
between the two sample types, neither of the measures of microbiota diversity tested were found
to be significantly associated with either ICU admission or LOS in the adjusted analyses within
either age group.

Top taxa from the 16s rRNA data:
Table 8 shows the top 26 taxa that had the highest mean relative abundance from either the SP or
NP/OP samples. Streptococcus was the most prevalent taxa in both samples comprising roughly
19 of the reads in both the NP/OP and SP samples. Genera previously implicated to play a role
or have increased abundance in the presence of CAP, including Prevotella, Veillonella, Rothia,
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Neisseria, Fusobacterium, Haemophilus, Moraxella and Actinomyces, were all found to rank
highly in relative abundance here as well (Chen, 2013; Garzoni, 2013; Sakwinska, 2014).
In an LDA analysis comparing the taxa between the NP/OP and the SP samples, genera
Atopobium, and family Actinomycetaceae were significantly enriched in the NP/OP samples of
both the older and the younger age groups, while phylum Bacteroidetes was significantly
enriched in the SP samples of both the older and the younger age group (Figure 1). Within the
younger age group, 7 taxa, along with the grouped rare taxa, were significantly enriched in the
NP/OP samples, and 3 taxa were significantly enriched within the SP samples. The older age
group had 4 taxa with significantly higher relative abundance in the NP/OP samples, and eight
significantly enriched in the SP samples.

3. Associations between individual taxa in SP samples and pneumonia disease severity.
Within the younger age group, Corynebacterium and Actinomyces were significantly enriched in
those children who had LOS shorter than four days (Figure 2a). In the adjusted analysis, patients
in the top quartile for relative abundance of Corynebacterium and Actinomyces were found to be
associated with shorter LOS after pneumonia diagnosis (OR= 0.30: 0.10-0.93, p=0.0372; OR=
0.30: 0.10-0.93, p=0.0372 respectively). Positive S. aureus culture was also found to be a
significant covariate in the younger age group and with a positive culture being associated with
LOS longer than four days (OR=4.96: 1.83-13.42, p=0.002). In the older age group,
Streptococcus, Atopobium, Moraxella, family Actinomycetaceae, Leptotrichia and family
Veillonellaceae were all significantly enriched in the samples of those children who had shorter
LOS (Figure 2b). However, in the adjusted analysis, none of the taxa were significantly
associated with longer LOS. Within the older age group, the high relative abundance of
Moraxella was found to be significantly associated a risk of ICU admission (OR=4.97: 1.10-
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22.50, p=0.037). In the final adjusted model for ICU admission in the older age group, recent flu
vaccination was found to be a significant covariate, with recent flu vaccination being positively
correlated with ICU admission (OR=4.83: 1.01-23.13, p=0.049). This was unexpected, but may
be due to those receiving the vaccination being more likely to have severe underlying conditions;
they may have been sicker to begin with.

4. Relationships between correlated taxa and pneumonia severity.
Within the microbiota, members of the commensal flora may co-aggregate or be more likely to
co-colonize based on similar nutritional requirements or the member’s use of various waste
products and secondary metabolites (Rickard et al., 2003; Willing et al., 2011). Thus, PCA was
used to identify groups of taxa (factors) that correlated with each other within each of the
stratified samples. The SP samples in the younger age group produced four independent factors
(Table 9), while PCA for the SP samples in the older age group produced five independent
factors (Table 10).

Stratified analysis in patients younger than five:
(i) Atopobium, Veillonella, Actinomycetaceae, and Actinomyces. As a group, the relative
abundance of these Factor 1 taxa, genera Atopobium, Veillonella, Actinomyces and the family
Actinomycetaceae, did not differ significantly by LOS outcome.
(ii) Leptotrichia, Capnocytophaga, Neisseria, Lactobacillales. Betaproteobacteria, Moraxella,
and rare taxa. The PCA Factor 2 taxa include genera Leptotrichia, Capnocytophaga, Neisseria,
Moraxella, suborder Lactobacillales, class Betaproteobacteria, and the rare taxa. However, the
relative abundance of these taxa as a group was not found to significantly differ with LOS
outcome.
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(iii) Mycoplasma, Veillonellaceae, Leptotrichiaceae and Bacteroidetes. Genera Mycoplasma,
families Veillonellaceae, Leptotrichiaceae and phylum Bacteroidetes are all positively correlated
with PCA factor 3. As a group, the taxa in factor 3 are significantly associated with shorter LOS
and appear to be protective (OR= 0.49: 0.26-0.91, p=0.023).
(iv) Moraxella, Corynebacterium, Dolosigranulum, Fusobacterium, Leptotrichiaceae and
Bacteroidales. The taxa in PCA factor 4, comprised of genera Moraxella, Corynebacterium,
Dolosigranulum, Fusobacterium, family Leptotrichiaceae and suborder Bacteroidales, appears
to be protective and is significantly associated with shorter LOS (OR=0.536: 0.30-0.96,
p=0.035). Genus Fusobacterium, family Leptotrichiaceae and suborder Bacteroidales are
negatively correlated with the factor 4, and a decrease in their relative abundance appears to be
protective against longer hospital stays. In contrast, the genera Moraxella, Corynebacterium and
Dolosigranulum are positively correlated with factor 4 in the younger children and an increase in
their relative abundance appears to be protective against longer LOS.

Stratified analysis in patients older than five:
(i) Veillonella, Atopobium, Actinomyces, Prevotella, Neisseria, and Pasteurellaceae. The
genera Veillonella, Atopobium, Actinomyces, Prevotella, Neisseria, and family Pasteurellaceae
comprise PCA factor 1 in the older children (Table 10). Taken as a group, the relative
abundance of Factor 1 taxa does not significantly differ by LOS or ICU admission.
(ii) Dolosigranulum, Corynebacterium, and Rothia. PCA factor 2 is comprised of
Dolsigranulum, Corynebacterium and Rothia, all of which are positively associated with the
factor. These taxa appear to be, as a group, associated with increased odds of longer LOS in the
older age group (OR=3.18: 1.15-8.85, p=0.026). In the final model, a 7-conjugate pneumonia
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vaccine was also found to be a significant protective covariate, with reduced odds of longer LOS
(OR=0.09: 0.02-0.36, p=<0.001).
(iii) Porphyromonadaceae, Lactobacillales, and Bacteroidales. Taken as a group, the taxa in
Factor 3, including the genera Dolosigranulum, Corynebacterium, and Rothia do not differ
significantly by LOS or ICU admission in the older age group.
(iv) Leptotrichia, Fusobacterium, and Leptotrichiaceae. The genera Leptrotrichia,
Fusobacterium, and family Leptotrichiaceae comprised PCA factor 4, and are positively
associated with the factor. As a group, the taxa in PCA factor 4 were found to be protective and
have a significantly decreased relative abundance in older children with longer LOS (OR=0.491:
0.242-0.999, p=0.049).
(v) Streptococcus, Gemella, and Prevotella. The taxa PCA Factor 5 were also not found to
significantly differ as a group with either ICU admission or LOS in the older age group.

5. Relationship between SP microbiota community types, predictive features of the
community types and pneumonia disease severity.
A separate approach to addressing the considerable interpersonal variation in the composition of
the lung microbiota is to use enterotypes or community types. Community typing acts by
clustering samples into bins based upon their taxonomic similarity, and reflect a network of cooccurring bacterial populations (Ding, 2014). Community types have been found to be
associated with a wide variety of environmental and behavioral characteristics, such as diet and
sexual activity, as well as diseases such as psoriasis and Trichomonas vaginalis (Ding, 2014).
Even more tellingly community types at one body site have been shown to be predictive of
community types at adjacent body sites (Ding, 2014). We generated community types for each
stratified population using the partitioning around the medoid approach (PAM). This resulted in
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three distinct community types being generated for the SP samples in the younger age group, and
two distinct community types in the older age group (Figure 3). In a logistic analysis, there was
no significant association between any of the community types and disease outcomes in the
younger age group. However, in the older age group, community type 2 was found to be highly
predictive of a longer LOS; though it was not possible to run the logistic model due to the
presence of small cell values (Table 11).
Using Random Forest plots, Moraxella, Dolosigranulum, Prevotella, Haemophilus and
Corynebacterium are all significantly discriminant features, and taken together account for 79%
of the total predictive value of the taxa to distinguish between community types 1 and 2 (data not
shown). Moraxella, Prevotella, Dolosigranulum, Corynebacterium and Haemophilus are all
more highly enriched in Community Type 2 than 1 (Figure 4) and are thus significantly
associated with a longer LOS. These findings appear to be both in support and contradiction
with some of the earlier findings; namely Corynebacterium’s presence runs counter to the LDA
results where the taxa was associated with shorter LOS in the older age group. Similarly,
Prevotella’s presence in Community Type 2 is in conflict with the earlier finding from the factor
analysis in which Prevotella positively associated with a protective Factor against longer LOS in
the older age group (Table 9). However, Dolosigranulum’s inclusion in Community Type 2 is
completely consisted with the PCA results in the older age group finding a positive association
with increased LOS.
Discussion:
Consistent with expectations, there were significant differences in the microbiota make-up
between the SP samples to the NP/OP samples. Interestingly, the NP/OP samples appeared to be
significantly more diverse within the younger age group, though the opposite effect, though less
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pronounced, was true for the older age group. It is not clear why this might be the case. Despite
these inter-sample differences, microbial diversity did not appear to have any significant impact
on the severity of pneumonia in either age group. Increased diversity of the microbiota is often
thought of as protective, as demonstrated by a recent study showing both decreased richness and
diversity was associated with pneumonia diagnosis in CAP pediatric patients (Sakwinska, 2014).
However, in pneumonia pathogenesis the results have been inconsistent and often inconclusive
(Toma, 2014; Hilty, 2010; Huang, 2013). A recent study examining high-risk vs. low-risk
patients for clinical pulmonary infection score in hospitalized adults found no significant
correlation between risk and the diversity of lung microbiota (Toma, 2014).
Streptococcus was the most prevalent taxa in both samples comprising roughly 19% of the reads
in both the NP/OP and SP samples. This is consistent with previous findings from 16s rRNA
data of CAP patients in both SP and NP/OP samples (Chen, 2013; Garzoni, 2013, Sakwinska,
2014). Genera Prevotella, Veillonella, Rothia, Neisseria, Fusobacterium, Haemophilus and
Actinomyces have all been previously reported to be highly prevalent in the NP/OP and SP
samples of CAP patients and were all found to rank highly here as well in relative abundance
(Chen, 2013; Garzoni, 2013). However, a recent Swiss study using NP/OP samples in CAP
pediatric patients found 92% of the reads were from Moraxella, Haemophilus and Streptococcus
alone (Sakwinska, 2014). While Streptococcus, Moraxella, and Haemophilus are ranked first,
fourth and ninth respectively in the NP/OP samples, and first, second and sixth in the SP
samples, the combined relative abundance of these pathogens are only 40.87% in this study. The
presence of genera Prevotella Veillonella and Rothia appear to be more consistent with the
previously mentioned studies of the U.S. young adult CAP population and may reflect a different
etiology of pneumonia in different areas. In contrast, Moraxella is commonly found in patients
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with pulmonary infections across studies and is found ranking highly in both the NP/OP and SP
samples, as well as Rothia (Chen, 2013, Sakwinska, 2014, Garzoni, 2013).
The results from the SP LDA and the community based analyses implicated several known CAP
pathogens as being associated with increased pneumonia severity. Previous studies have found
that Moraxella, S. pneumonia and S. aureus are major causes of CAP within a younger
population (Hashemi, 2010). Here in this study, positive S. aureus culture was strongly
associated with longer LOS in the fully adjusted analysis using LDA in the younger age group.
It is not terribly surprising to find that the presence of a known CAP pathogen would be
associated with poorer outcomes, especially given studies indicating the increased risk associated
with co-infections of known CAP pathogens. From the community typing, Moraxella and
Haemophilus were more highly enriched in Community Type 2, which was strongly associated
with a longer LOS in the older age group. Moraxella and Haemophilus are both known CAP
pathogens, and are known to be associated with CAP in the pediatric population (Hashemi, 2010;
Chen, 2013; Vissing, 2013). Previous studies have shown that Moraxella is a pnuemonia
causing pathogen in children with CAP (Hashemi, 2010). Moraxella is absent in the lower
respiratory tract of healthy individuals, but recent studies have found it to be present in patients
diagnosed with CAP (Chen, 2013). Most of the results in this study are consistent with the idea
that Moraxella is a CAP pathogen, including the LDA analysis in the older children finding
Moraxella to be positively associated with ICU admission, and the Community Typing results
again in the older children. However, within in the younger children, PCA factor results pointed
towards Moraxella being a part of a factor associated with shorter LOS. A note of caution
should enter here that the community analyses can only infer that a factor as a whole is
associated with a protective role, and that it may not be Moraxella driving the association seen in
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this result, but the other taxa in the factor. Given that lung colonization of Moraxella has been
shown to be associated with an increased risk of pneumonia in neonates and early life children
independent of asthma (Vissing, 2013), caution should be employed in the interpretation of this
result. Overall, the weight of the evidence from the various community analyses do point to
Moraxella playing a role in CAP severity, and increased bacterial load is associated with more
severe infection and pneumonia severity.
Interestingly, the PCA SP analysis in the younger children indicated that the phylum
Bacteroidetes, positively correlated with the protective PCA Factor 3, was associated with
reduced LOS. This phylum has previously been shown to play a protective role against
pneumonia severity (Huang, 2013) and has previously been described as being less frequently
found within asthmatic populations, attributed to its function of preventing against pathogenic
invasion (Huang, 2013). These findings suggest that Bacteroidetes may play a similar role in
pneumonia severity, possibly by interfering with the colonization of the lung by pathogenic
bacteria. Similarly, previous studies have implicated Prevotella in playing a protective role
against pathogenic invasion in pediatric patients, the presence of Prevotella was implicated as
playing a protective role in the PCA analysis in the older age group, where it was positively
associated with Factor 4 which was protective against longer LOS (Huang, 2013). However,
Prevotella was also a significantly predictive feature of Community Type 2 in the older children,
and associated, in this analysis, with longer LOS. Again, this result highlights the need for
caution in interpreting the results from the community analyses and suggest that there are likely
complex interactions at work that will require multiple different analytical approaches to
determine their full extent.
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Other taxa that emerged from the SP analysis include Rothia and Dolosigranulum, which here
was found to be associated with Factor 2 in the older age group that was significantly associated
with longer LOS, and consistently Dolosigranulum was again found to be associated with
Community Type 2 from the community typing. These results were consistent with previous
studies where Rothia was identified as a possible infective agent of CAP, although it is a normal
part of the flora in the oral cavity and upper respiratory tract (Chen, 2013). The increased
presence of Rothia in those with longer LOS may be an indication of a more severe pneumonia
infection.
Lastly, Corynebacterium was found in increased relative abundance in Community Type 2 and
thus potentially associated with longer LOS in older kids, however this was in contrast to the
LDA results where Corynebacterium and Actinomycs were associated with a shorter LOS in the
younger age group. Here, the community typing results were more consistent with previous
findings that the phylum Actinobacteria, of which both Corynebacterium and actinomyces are a
part, was positively associated with a CAP diagnosis as compared to a healthy population (Chen,
2013). Taken together, all of these finding highlight the complexity of the relationships between
various microbes and raises the need for caution in being to quick to interpret the results from
various microbiome analyses. However, despite this, there was still remarkable consistency
between many of the findings in this study and previous literature investigating the role of the
microbiome and pneumonia etiology with the risk of developing pneumonia.
Conclusion:
The asthmatic pediatric population represents an at-risk population for recurrent CAP pneumonia
(Patria, 2013). A disturbed lung microbiota has been implicated to play a role in the onset and
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progression of asthma (Lu, 2014; Specjalski, 2011; Hilty, 2010; Huang, 2013) as well as being
associated with, and increasing the risk of developing pneumonia (Vissing, 2013; Sakwinska,
2014). Thus, it is likely that the altered status of the lung microbiota in asthmatic patients plays a
role in the susceptibility of asthmatics to pneumonia. This study is the first to look at significant
predictors within the microbiome of pneumonia disease severity within the pediatric asthmatic
population.
Taken as a whole, this study found that many of the previously identified features of the
microbiome known to be predictive of developing CAP or associated with the presence of CAP,
were the same features that were predictive of poor CAP disease outcomes in the pediatric
population, such as a longer LOS and ICU admission. These include increased relative
abundances of the known CAP pathogens, including Moraxella, S. pneumoniae, S. aureus and
Haemophilus, being associated with increased odds of poorer disease outcomes, both LOS and
ICU admission. Similarly, Bacteroidetes’ association with shorter LOS and Rothia’s association
with longer LOS are both consistent with previous characterizations of the bacteria in the onset
of pneumonia and asthma (Huang, 2013; Chen, 2013).
Corynebacterium was twice found to be associated with poor disease outcomes in the older age
group; once in the Community Type analysis with longer LOS, and once as a part of PCA factor
2 with longer LOS; though it appears that Corynebacterium was positively associated with the
protective PCA factor 4 in the younger age group. It is not clear why this disparity emerged
between the two age groups, but previous studies have shown Corynebacterium is positively
associated with CAP diagnosis (Chen, 2013). Moraxella was another taxa frequently present in
the analyses.
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Moraxella, a known minor pneumonia causing pathogen, including in the pediatric CAP
population (Hashemi, 2010; Chen, 2013), had a similar finding to that of Corynebacterium.
Moraxella was associated with increased risk of ICU admission in the older age group from the
LDA analysis, and with increased odds of longer LOS in the older age group through its
association with Community Type 2. However, from the PCA analysis in the younger age
group, Moraxella was positively associated with Factor 4, which was found to be protective
against a longer LOS. These inconsistencies in the data analysis highlight the complex nature of
the relationships between the different bacteria in the microbiota. Each type of analysis has its
own strengths and weaknesses, and seeks to highlight a different aspect of the relationship within
the microbiome. It is possible that some of the differences in the role of each taxa is influenced
by the lens through which it is examined. Prior studies have demonstrated microbiome results
are sensitive to the methods being used, and that methods vary in their ability to detect clusters
(Kuczynski, 2010). Alternative explanations may be that the younger age group represents a
different population of asthmatics than the older children, and that taxa found to be associated
with poorer pneumonia outcomes in older children may perform a different role within the
younger age group.
However, simply detecting the presence of a microbe within the upper respiratory tract does not
necessarily mean that it is the cause of the pneumonia nor that it is inhabiting the lower airways
(Murdoch, 2012). Previous studies have shown that SP cultures have a high sensitivity and
specificity for pneumococcal pneumonia in adults, however it is still uncertain whether these
specimens are of equal value for children (Murdoch, 2012). SP samples, if collected poorly, can
be highly contaminated with upper respiratory tract microbes, though tests exist to evaluate the
quality of the specimens. Similarly, some pneumonia pathogens identified from nasopharyngeal
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tract specimens may often been associated with incidental carriage, while other, more invasive,
serotypes have a higher positive predictive value for pneumonia etiology (Murdoch, 2012).
However, NP/OP samples have a high negative predictive value and are of still of value in a
clinical setting. In our study, the microbiota present in the SP samples appeared to be
consistently less rich and diverse than those of the NP/OP samples and were successfully
colonized by many of the known CAP pathogens.
Limitations
There are several limitations to this study: (i) The data in this study was cross-sectional and taken
after the onset of disease, and thus this study can only determine that certain taxa or groups of
taxa are associated with poorer pneumonia outcomes in asthmatic children. Longitudinal studies
are needed to determine the temporal associations and infer causality. (ii) Due to the difficulties
surrounding asthma diagnosis in children under the age of five, it is possible that the younger age
group likely represents a more heterogeneous population with unknown factors affecting their
risk for pneumonia and may limit the ability to interpret the differences between the two age
groups.
Overall, this study demonstrates that SP samples have the potential to be used within the
pediatric population as a non-invasive surrogate for the lung microbiome. Though further
studies are needed to refine and further understand the complicated relationships between the
various taxa, and care should be used in deciding which population of children are being
assessed. However, this study has shown that many of the same features that are associated with
the onset and presence of CAP may also be used to predict the progression of the disease.
Asthma exacerbations are associated with increased health care costs among patients, and these
exacerbations can often be caused by infections with CAP pathogens (Ivanova, 2012). These
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excess costs of treating an asthmatic patient with CAP result in nearly double the costs as
compared to those patients without asthma, representing a significant opportunity for targeted
interventions to avoid excess medical and productivity costs (Polsky, 2012).
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Table 1. Age-stratified descriptive statistics for demographic characteristics, clinical
characteristics and vaccination history, including unadjusted associations with LOS >4 days.
Length of Stay
Age <5 years
Age ≥ 5 years
< 4 days
N=91+
Sex
Female
Male
Race
White
Black
Other
Education*
<high school
High school/Some College
College and graduate
Admitted From
Home
Outpatient Clinic
Another Hospital

39
52

(42.9)
(57.1)

≥ 4 days
N=35+
17
18

pvalue
0.563

(48.6)
(51.4)

< 4 days
N=58+
23
35

(39.7)
(60.3)

≥ 4 days
N=19+
10
9

(52.6)
(47.4)

0.014
7
80
4

(7.7)
(87.9)
(4.4)

4
24
7

(9.4)
(68.6)
(20.0)

0.188
7
49
2

(12.1)
(84.5)
(3.5)

0 (0.0)
19 (100.0)
0 (0.0)

0.653
8
72
9

(9.0)
(80.9)
(10.1)

5
26
4

(14.3)
(74.3)
(11.4)

0.315
6
35
15

(10.7)
(62.5)
(26.8)

0
14
5

(0.0)
(73.7)
(26.3)

0.629
74
6
10

(82.2)
(6.7)
(11.1)

30
3
2

(85.7)
(8.6)
(5.7)

Co-morbidities
Yes
No

18
73

(19.8)
(80.2)

12
23

(34.3)
(65.7)

Prior Antibiotics*
Yes
No

25
66

(27.5)
(72.5)

8
27

(22.9)
(77.1)

0.675
41
5
11

(71.9)
(8.8)
(19.3)

13
3
3

(68.4)
(15.8)
(15.8)

0.087

0.127
6
52

(10.3)
(89.7)

5
14

(26.3)
(73.7)

8
50

(13.8)
(86.2)

4
15

(21.1)
(79.0)

0.598

Oral Steroids*
Yes
No

13
77

(14.4)
(85.6)

7
27

(20.6)
(79.4)

Inhaled Steroids*
Yes
No

19
60

(24.1)
(76.0)

6
25

(19.4)
(80.7)

Vaccines:
Seasonal Influenza *
Yes
No

21
66

(24.1)
(75.9)

12
23

(34.3)
(65.7)

0.476

0.407

0.157
7
51

(12.1)
(87.9)

5
14

(26.3)
(73.7)

27
26

(50.9)
(49.1)

10
9

(52.6)
(47.4)

11
46

(19.3)
(80.7)

3
16

(15.8)
(84.2)

0.597

0.900

0.254

Pneumococcal -7 or 13 conjugate*
Yes
No

89
1

(98.9)
(1.1)

35 (100.0)
0 (0.0)

H. influenza B *
Yes
No

87
3

(96.7)
(3.3)

34
1

0.956

0.720

0.004
52
6

(89.7)
(10.3)

11
8

(57.9)
(42.4)

57
1

(98.3)
(1.7)

18
1

(94.7)
(5.3)

1.000
(97.1)
(2.9)

pvalue
0.321

0.435

* Numbers may not sum to total due to missing values
+ Restricted to population to those diagnosed with asthma, radiologically confirmed pneumonia and having both np and sp samples.
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Table 2. Descriptive statistics for demographic characteristics, clinical characteristics and
vaccination history, including unadjusted associations for ICU admission in the older age group.
ICU Admission
Age ≥ 5 years
Not Admitted
Admitted
+
p-value
n = 68
n = 9+
Sex
0.413
Female
28 (41.2)
5 (55.6)
Male
40 (58.8)
4 (44.4)
Race
White
Black
Other
Education*
<high school
High school/Some College
College and graduate
Admitted From
Home
Outpatient Clinic
Another Hospital

0.509
7 (10.3)
59 (86.8)
2 (2.9)

0 (0.0)
9 (100.0)
0 (0.0)
0.156

5 (7.6)
41 (62.1)
20 (30.3)

1 (11.1)
8 (88.9)
0 (0.0)
0.833

47 (70.2)
7 (10.5)
13 (19.4)

7 (77.8)
1 (11.1)
1 (11.1)

Co-morbidities
Yes
No

0.469
9 (13.2)
59 (86.8)

2 (22.2)
7 (77.8)

Prior Antibiotics*
Yes
No

11 (16.2)
57 (83.8)

1 (11.1)
8 (88.9)

0.694

Oral Steroids*
Yes
No

0.559
10 (14.7)
58 (85.3)

2 (22.2)
7 (77.8)

Inhaled Steroids*
Yes
No

30 (47.6)
33 (52.4)

7 (77.8)
2 (22.2)

Vaccines:
Seasonal Influenza *
Yes
No

10 (14.9)
57 (85.1)

4 (44.4)
5 (55.6)

0.090

0.032

Pneumococcal -7 or 13 conjugate *
Yes
No

0.738
56 (82.4)
12 (17.7)

7 (77.8)
2 (22.2)

H. influenza B *
Yes
No

67 (98.5)
1 (1.5)

8 (88.9)
1 (11.1)

0.088

* Numbers may not sum to total due to missing values
+ Restricted to population to those diagnosed with asthma, radiologically confirmed pneumonia and having both np and sp samples.
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Table 3. Age-stratified unadjusted associations with LOS >4 days for CAP bacterial sputum
cultures.
Length of Stay
Age <5 years
Age ≥ 5 years

S. pneumoniae
Yes
No
S. aureus
Yes
No
M. catarrhalis
Yes
No
H. Influenzae
Yes
No

< 4 days
N=91

≥ 4 days
N=35

18 (19.8)
73 (80.2)

9 (25.7)
26 (74.3)

10 (11.0)
81 (89.0)

13 (37.1)
22 (62.9)

pvalue
0.467

< 4 days
N= 58

≥ 4 days
N=19

3 (5.2)
55 (94.8)

0 (0.0)
19 (100.0)

12 (20.7)
46 (79.3)

3 (15.8)
16 (84.2)

<0.001

0.750

0.655
20 (22.0)
71 (78.0)

9 (25.7)
26 (74.3)

12 (13.2)
79 (86.8)

8 (22.9)
27 (77.1)

pvalue
0.571

1.000
2 (3.5)
56 (96.6)

0 (0.0)
19 (100.0)

3 (5.2)
55 (94.8)

2 (10.5)
17 (89.5)

0.183

0.592

Table 4. Unadjusted associations with ICU admission for CAP bacterial sputum cultures within
the older age group.
ICU Admission
Age ≥ 5 years
Not Admitted
Admitted
n = 68
n=9
S. pneumoniae
Yes
No

3 (4.4)
65 (95.6)

0 (0.0)
9 (100.0)

S. aureus
Yes
No

14 (20.6)
54 (79.4)

1 (11.1)
8 (88.9)

p-value
0.520

0.246

M. catarrhalis
Yes
No

0.602
2 (2.9)
66 (97.1)

0 (0.0)
9 (100.0)

H. Influenzae
Yes
No

5 (7.4)
63 (92.7)

0 (0.0)
9 (100.0)

0.400
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Table 5. Age-stratified, unadjusted associations with LOS for the bacterial cultures of sputum
samples and viral PCR results on nasopharyngeal/oropharyngeal samples.
Length of Stay

Mycoplasma
Yes
No
Viruses:
Rhinovirus
Combined
Alone
None
RSV
Yes
No

< 4 days
N=91

Age <5 years
≥ 4 days
N=35

2 (2.2)
89 (97.8)

0 (0.0)
35 (100.0)

pvalue
1.000

< 4 days
N= 58

Age ≥ 5 years
≥ 4 days
N=19

5 (8.6)
53 (91.4)

0 (0.0)
19 (100.0)

0.161
24 (26.4)
18 (19.8)
49 (53.9)

7 (20.0)
3 (8.6)
25 (71.4)

0.432
10 (17.2)
27 (46.6)
21 (36.2)

2 (10.5)
7 (36.8)
10 (52.6)

0.911
38 (41.8)
53 (58.2)

15 (42.9)
20 (57.1)

Adenovirus
Yes
No

23 (25.3)
68 (74.7)

6 (17.1)
29 (82.9)

Coronavirus
Yes
No

10 (11.0)
81 (89.0)

3 (8.6)
32 (91.4)

Parainfluenzae
Yes
No

5 (5.5)
86 (94.5)

1 (2.9)
34 (97.1)

Metapneumovirus
Yes
No

4 (4.4)
87 (95.6)

3 (8.6)
32 (91.4)

pvalue
0.325

0.674
6 (10.3)
52 (89.7)

1 (5.3)
18 (94.7)

0.331

1.000
3 (5.2)
55 (94.8)

1 (5.3)
18 (94.7)

2 (3.5)
56 (96.6)

1 (5.3)
18 (94.7)

4 (6.9)
54 (93.1)

0 (0.0)
19 (100.0)

1 (1.7)
57 (98.3)

0 (0.0)
19 (100.0)

0.987

0.988

0.865

0.567

1.000
0.396
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Table 6. Unadjusted associations with ICU admission for the bacterial cultures of sputum
samples and viral PCR results on nasopharyngeal/oropharyngeal samples.
ICU Admission
Age ≥ 5 years
Not Admitted
Admitted
n = 68
n=9
Mycoplasma
Yes
No

5 (7.4)
63 (92.7)

0 (0.0)
9 (100.0)

Viruses:
Rhinovirus
Combined
Alone
None

10 (14.7)
30 (44.1)
28 (41.2)

2 (22.2)
4 (44.4)
3 (33.3)

RSV
Yes
No

7 (10.3)
61 (89.7)

0 (0.0)
9 (100.0)

Adenovirus
Yes
No

3 (4.4)
65 (95.6)

1 (11.1)
8 (88.9)

Coronavirus
Yes
No

2 (2.9)
66 (97.1)

1 (11.1)
8 (88.9)

Parainfluenzae
Yes
No

3 (4.4)
65 (95.6)

1 (11.1)
8 (88.9)

Metapneumovirus
Yes
No

1 (1.5)
67 (98.5)

0 (0.0)
9 (100.0)

pvalue
0.400

0.815

0.313

0.395

0.234

0.395

0.714
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Table 7. Relationship between evenness and Shannon diversity indices and the
nasopharyngeal/oropharyngeal (NP/OP) and sputum (SP) samples in the age-stratified
population. T-tests were performed on the mean difference between the diversity indices in the
SPand NP/OP samples and presented with standard deviation (std) and p-values.

Eveness
Shannon Index

Total:
Mean Difference
(SP-NP/OP: ± std)
n = 203
p-value
0.031
-0.022
± 0.141
-0.272
± 0.993

<0.001

Age Stratification
0 - < 5 years:
≤ 5 to <18 years:
Mean Difference
Mean Difference
(SP-NP/OP: ± std)
(SP-NP/OP: ± std)
n = 126
p-value
n = 77
p-value
-0.056
± 0.140

<0.001

0.035
± 0.126

0.018

-0.530
± 1.022

<0.001

0.150
± 0.782

0.097
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Table 8. Top 26 mean-ranked taxa within the nasopharyngeal/oropharyngeal (NP/OP) samples
and the sputum (SP) samples based upon the 16s rRNA data for the population as a whole. The
cutoff for inclusion was 0.6 mean-relative abundance in either the SP or the NP/OP samples.
Sputum Samples
Ranking
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
a
Phylum
b
Family
c
Class
d
Suborder

Taxa
Streptococcus
Moraxella
Prevotella
Pasteurellaceaeb
Haemophilus
Veillonella
Neisseria
Fusobacterium
Porphyromonadace
aeb
Rothia
Bacteroidetesa
Actinomyces
Bacteroidalesd
Leptotrichia
Gemella
Lactobacillalesd
Capnocytophaga
Leptotrichiaceaeb
Betaproteobacteriac
Veillonellaceaeb
Mycoplasma
Corynebacterium
Dolosigranulum
Actinomycetaceaeb
Atopobium
Lactobacillus

Mean
(%)
24.11
12.22
10.23
7.78
6.67
4.75
3.95
3.14
2.14
1.98
1.96
1.48
1.44
1.33
1.28
1.00
0.96
0.91
0.85
0.72
0.69
0.68
0.60
0.32
0.28
0.07

Nasopharyngeal Samples
STD
(%)
18.8
22.99
12.62
12.61
14.13
5.210
6.81
3.83
3.16
3.21
3.13
2.41
1.97
1.87
1.81
1.94
2.33
1.57
2.30
1.24
5.08
1.65
1.83
0.74
0.62
0.53

Taxa
Streptococcus
Prevotella
Veillonella
Moraxella
Rothia
Pasteurellaceaeb
Neisseria
Actinomyces
Haemophilus
Lactobacillalesd
Dolosigranulum
Corynebacterium
Gemella
Fusobacterium
Porphyromonadaceaeb
Bacteroidalesd
Leptotrichia
Bacteroidetesa
Atopobium
Actinomycetaceaeb
Leptotrichiaceaeb
Capnocytophaga
Veillonellaceaeb
Betaproteobacteriac
Lactobacillus
Mycoplasma

Mean
(%)
32.68
10.91
7.74
5.89
5.18
2.76
2.41
2.40
2.30
2.08
2.05
2.02
1.75
1.55
1.54
1.30
0.97
0.93
0.92
0.92
0.70
0.69
0.52
0.34
0.10
0.02

STD
(%)
19.2
10.60
6.083
13.2
6.035
5.25
4.76
2.48
6.42
2.74
4.97
6.05
3.04
2.23
2.94
1.91
1.75
2.04
1.40
1.51
1.52
2.60
0.67
1.14
0.69
0.06
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a.

b.
Figure 1. Linear discriminant analysis (LDA) showing taxa significantly enriched in the sputum
samples (red) and the nasopharyngeal/oropharyngeal samples (green). a. LDA results in the
younger age group. b. LDA results in the older age group.
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a.

1

1

b.
Figure 2. Results from the Linear Discriminant Analysis performed on the sputum samples
showing significantly enriched taxa in patients with LOS <4 days (red). a. LDA sputum results
in the younger age group. b. LDA sputum results in the older age group.
1
Family
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Table 9. PCA Factors for the sputum samples in the younger age group. 1 Factor significantly
associated with shorter LOS in younger age group, p<0.05. 2 Category combining rare and
unclassified bacteria.
Sputum, <5 years
Factor 1
Factor 2
Factor 3 1
Factor 4 1
Atopobium
88
Veillonella
83
b
Actinomycetaceae
83
Actinomyces
81
Leptotrichia
64
Capnocytophaga
63
Neisseria
54
2
Other rare taxa
53
d
Lactobacillales
49
Betaproteobacteriac
48
Moraxella
-41
41
Veillonellaceaeb
83
Bacteroidetesa
80
Mycoplasma
55
Leptotrichiaceaeb
50
-43
Fusobacterium
-50
d
Bacteroidales
-40
Corynebacterium
74
Dolosigranulum
75
a
Phylum
b
Family
c
Class
d
Suborder
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Table 10. PCA Factors for the sputum samples in the older age group. 1, 2 Factor significantly
associated with shorter and longer LOS in older age group, respectively (p<0.05). 3 No factors
were significantly associated with ICU admission in older age group.
Sputum, ≥ 5 years
Veillonella
Atopobium
Actinomyces
Prevotella
Pasteurellaceaeb
Neisseria
Dolosigranulum
Corynebacterium
Rothia
Porphyromonadaceaeb
Lactobacillalesd
Bacteroidalesd
Leptotrichia
Fusobacterium
Leptotrichiaceaeb
Streptococcus
Gemella
b
Family
d
Suborder

Factor 1
79
71
55
51
-50
-56

Factor 2 1

Factor 3

Factor 4 2

Factor 5

-58

86
75
72
84
81
55
74
71
64
87
62
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a.
b.
Figure 3. Principal Coordinate Analysis generating the community types from the clustering of
sputum samples. a. Three distinct community types from clustering within the younger age
group. b. Two distinct community types from clustering within the older age group.
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Sputum Community Type Make-up in
≥5 Age Group

1

Community Type:

2

Figure 4. Heat map of the makeup of the two sputum community types within the older pediatric
study population. The heat map represents the proportion of subjects within each community
type within the top quartile of each taxa’s relative abundances.
(_P) = Phylum
2 (_F) = Family
(_C) = Class
(_O) = Suborder

Table 11. Contingency table for LOS outcome by sputum sample Community Type in the older
age group.
Sputum ≥ 5 years:
LOS
Total
Community Type
≥ 4 days
< 4 days
1
2

5
19

52
1

57
20
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